Johnson & Johnson (JNJ)

Industry Drug Manufacturers - General

This stock can be held in an Investment ISA and an Investment Account

Sell

$242.70

Buy

$243.00

arrow-down$-1.08 (-0.44%)

Prices updated at 03 Apr 2026, 00:59 EDT

Prices minimum 15 mins delay

Prices in USD

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices segments.

S&P 500

0.11%

NYSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Drug Manufacturers - General

Chairman

Mr. Timothy Schmid

CEO

Mr. Joaquin Duato

Most recent earnings

31 Dec 2025

Fiscal year end

31 Dec 2025

Employees

140,800

Head office

One Johnson & Johnson Plaza

New Brunswick

United States

08933

+1 732 524-0400

investor-relations@its.jnj.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Dr. John C. Reed,M.D.,PhD Executive Vice President, Innovative Medicine, R&D	1.22m
Mr. John G. Morikis Independent Director	0.04m
Ms. Marillyn A. Hewson Lead Independent Director	0.20m
Dr. Paula A. Johnson,M.D. Independent Director	0.13m
Mr. Hubert Joly Independent Director	0.14m
Mr. Daniel Eduardo Pinto Independent Director	0.06m
Dr. Mary C. Beckerle, PhD Independent Director	0.15m
Dr. Mark B. McClellan, M.D.,PhD Independent Director	0.13m
Mr. Joaquin Duato Chairman of the Board and Chief Executive Officer	1.60m
Dr. Jennifer A. Doudna, PhD Independent Director	0.13m
Mr. Joseph J. Wolk, C.P.A. Executive Vice President and Chief Financial Officer	1.24m
Mr. James D. Swanson Executive Vice President and Chief Information Officer	-
Ms. Jennifer L. Taubert Executive Vice President and Worldwide Chairman, Innovative Medicine	1.22m
Ms. Kathryn E. Wengel Executive Vice President and Chief Technical Operations and Risk Officer	-
Mr. Eugene A. Woods Independent Director	0.14m
Dr. Nadja Y. West, M.D. Independent Director	0.13m
Mr. Mark A. Weinberger Independent Director	0.15m
Mr. Robert J. Decker, Jr Controller and Chief Accounting Officer	-
Ms. Vanessa Broadhurst Executive Vice President, Global Corporate Affairs	-
Ms. Elizabeth Forminard Executive Vice President and Chief Legal Officer	-
Mr. Timothy Schmid Executive Vice President and Worldwide Chairman, MedTech	0.94m
Ms. Kristen Mulholland Executive Vice President and Chief Human Resources Officer	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Vanguard Group Inc	240,349,660
BlackRock Inc	207,261,021
State Street Corp	132,206,061
JPMorgan Chase & Co	117,281,712
Vanguard	84,657,939

Director dealings

Date chevron-l-regular chevron-r-regular	Action
09 Dec 2025	-
09 Dec 2025	-
09 Dec 2025	-
26 Nov 2025	-
17 Oct 2025	-
17 Oct 2025	-
17 Oct 2025	-
09 Sep 2025	-
09 Sep 2025	-
09 Sep 2025	-
04 Sep 2025	-
04 Sep 2025	-
04 Sep 2025	-
29 Aug 2025	-
29 Aug 2025	-
29 Aug 2025	-
22 Aug 2025	-
22 Aug 2025	-
22 Aug 2025	-
15 Aug 2025	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.